Art. -Nr.: HY-116969

22(R)-Hydroxycholesterol

Name: 22(R)-Hydroxycholesterol
Brand: MedChemExpress
SKU: HY-116969
Price: 76.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: Narthesterol)

Kundenbewertung

Based on 1 Customer Validation

22 (R)-Hydroxycholesterol (Narthesterol) is a natural oxysterol, acting as a LXRα agonist that inhibits cancer cell proliferation. 22 (R)-Hydroxycholesterol activates LXRα-mediated upregulation of downstream ABCA1 expression, enhances apolipoprotein-dependent cholesterol efflux, reduces intracellular cholesterol content, and decreases the production of β-amyloid peptide. 22 (R)-Hydroxycholesterol induces the differentiation of human mesenchymal stem cells into functional dopaminergic neurons. 22 (R)-Hydroxycholesterol is applicable to research related to cancer, Alzheimer's disease, and Parkinson's disease.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.86%
CAS. Nr.: 17954-98-2
Formel: C₂₇H₄₆O₂
Molecular Weight:402.65

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

22(R)-Hydroxycholesterol Chemical Structure

CAS. Nr.: 17954-98-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]

LXRα

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
DU-145	EC50	7.0 μM	Antiproliferative activity against human DU-145 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation. Antiproliferative activity against human DU-145 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation.	20944148
MCF7	EC50	7.4 μM	Antiproliferative activity against human MCF-7 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation. Antiproliferative activity against human MCF-7 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation.	20944148
SAOS-2	EC50	7.6 μM	Antiproliferative activity against human Saos-2 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation. Antiproliferative activity against human Saos-2 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation.	20944148
HeLa	EC50	7.7 μM	Antiproliferative activity against human HeLa cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation. Antiproliferative activity against human HeLa cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation.	20944148
PC-3	EC50	7.7 μM	Antiproliferative activity against human PC-3 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation. Antiproliferative activity against human PC-3 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation.	20944148
MDA-MB-435	EC50	8.0 μM	Antiproliferative activity against human MDA-MB-435 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation. Antiproliferative activity against human MDA-MB-435 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation.	20944148
NCI-H1299	EC50	8.4 μM	Antiproliferative activity against human H1299 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation. Antiproliferative activity against human H1299 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation.	20944148
A-431	EC50	8.6 μM	Antiproliferative activity against human A431 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation. Antiproliferative activity against human A431 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation.	20944148
HepG2	EC50	10.1 μM	Antiproliferative activity against human HepG2 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation. Antiproliferative activity against human HepG2 cancer cells assessed as reduction in relative DNA content measured via Hoechst 33258 fluorescence after 96 hrs incubation.	20944148

In Vitro

22 (R)-Hydroxycholesterol (22R) (10‑20 μM; 24 h) combined with 9‑cis‑Retinoic acid (HY-15128) upregulates ABCA1 expression, enhances cholesterol efflux, modulates APP processing, and diminishes Aβ secretion in H4APPsw and CHOAPPsw cells^[1].
22 (R)-Hydroxycholesterol (22-HC) (2 μM; 14 days) induces the differentiation of human BM-MSCs, AD-MSCs and DP-MSCs into dopaminergic neurons. Among them, DP-MSCs show the highest differentiation efficiency (80.20% of MAP2-positive cells), with the most significant upregulation of dopaminergic markers and functional properties^[2].
22 (R)-Hydroxycholesterol (30 nM-3 μM) activates LXRα in transfected HEK293 cells. Significant activation is observed at a concentration of 1 μM, and an even higher level of activation is detected at 3 μM^[3].
22 (R)-Hydroxycholesterol (1-12 μM; 96 h) inhibits the proliferation of the human prostate cancer cell subline LNCaP in a dose-dependent manner, with an EC₅₀ value ranging from 4.7 μM to 6.3 μM; it also inhibits the proliferation of various human cancer cell lines in a dose-dependent manner, with EC₅₀ values ranging from 7.0 μM to 10.1 μM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Differentiation Assay^[2]

Cell Line:

human bone marrow-derived mesenchymal stem cells (BM-MSCs), adipose tissue-derived mesenchymal stem cells (AD-MSCs), dental pulp-derived mesenchymal stem cells (DP-MSCs)
Concentration:

2 μM
Incubation Time:

14 days
Result:

Induced dopaminergic neuronal differentiation of human BM-MSCs, AD-MSCs, and DP-MSCs, with DP-MSCs exhibiting the highest differentiation efficiency (80.20% MAP2-positive cells) and most robust upregulation of dopaminergic markers and functional traits.

Cell Proliferation Assay^[3]

Cell Line:

LNCaP human prostate cancer cell sublines (104-S, 104-R1, 104-R2, R1Ad, CDXR-3, IS-3)
Concentration:

1 μM, 2 μM, 4 μM, 8 μM, 12 μM
Incubation Time:

96 h
Result:

Dose-dependently suppressed the proliferation of all tested cell sublines.
Achieved half-maximal effective concentration (EC₅₀) values for growth inhibition of 4.7 μM (104-R2), 5.2 μM (CDXR-3), 5.7 μM (104-S), 5.8 μM (104-R1), 5.9 μM (IS-3), and 6.3 μM (R1Ad).

Cell Proliferation Assay^[3]

Cell Line:

multiple human cancer cell lines (DU-145, SCC13, MCF-7, Saos-2, HeLa, PC-3, MDA-MB-435, H1299, A431, HepG2)
Concentration:

1 μM, 2 μM, 4 μM, 8 μM, 12 μM
Incubation Time:

96 h
Result:

Dose-dependently suppressed the proliferation of all tested cell lines, with greater suppression observed at 8 μM or higher concentrations.
Achieved half-maximal effective concentration (EC₅₀) values for growth inhibition of 7.0 μM (DU-145), 7.2 μM (SCC13), 7.4 μM (MCF-7), 7.6 μM (Saos-2), 7.7 μM (HeLa), 7.7 μM (PC-3), 8.0 μM (MDA-MB-435), 8.4 μM (H1299), 8.6 μM (A431), and 10.1 μM (HepG2).

Related Protocols :

Chemical Information

CAS. Nr. 17954-98-2
Appearance Solid
Molecular Weight 402.65
Formel C₂₇H₄₆O₂
Color White to off-white
SMILES

O[C@@H](CC[C@@]12C)CC1=CC[C@@]3([C@@]2(CC[C@]4([C@]3(CC[C@]4([H])[C@H](C)[C@@H](CCC(C)C)O)[H])C)[H])[H]
Synonyms

Narthesterol
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

Ethanol : ≥ 100 mg/mL (248.35 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4835 mL

12.4177 mL

24.8355 mL

5 mM

0.4967 mL

2.4835 mL

4.9671 mL

10 mM

0.2484 mL

1.2418 mL

2.4835 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.21 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Koldamova RP, et al. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem. 2003 Apr 11;278(15):13244-56. [Content Brief]

[2]. Singh M, et al. 22(R)-hydroxycholesterol for dopaminergic neuronal specification of MSCs and amelioration of Parkinsonian symptoms in rats. Cell death discovery. 2021 Jan 16;7(1):13.

[3]. Chuu CP, et al. Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines. Anticancer research. 2010 Sep;30(9):3643-8.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol	1 mM	2.4835 mL	12.4177 mL	24.8355 mL	62.0887 mL
	5 mM	0.4967 mL	2.4835 mL	4.9671 mL	12.4177 mL
	10 mM	0.2484 mL	1.2418 mL	2.4835 mL	6.2089 mL
	15 mM	0.1656 mL	0.8278 mL	1.6557 mL	4.1392 mL
	20 mM	0.1242 mL	0.6209 mL	1.2418 mL	3.1044 mL
	25 mM	0.0993 mL	0.4967 mL	0.9934 mL	2.4835 mL
	30 mM	0.0828 mL	0.4139 mL	0.8278 mL	2.0696 mL
	40 mM	0.0621 mL	0.3104 mL	0.6209 mL	1.5522 mL
	50 mM	0.0497 mL	0.2484 mL	0.4967 mL	1.2418 mL
	60 mM	0.0414 mL	0.2070 mL	0.4139 mL	1.0348 mL
	80 mM	0.0310 mL	0.1552 mL	0.3104 mL	0.7761 mL
	100 mM	0.0248 mL	0.1242 mL	0.2484 mL	0.6209 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

22(R)-Hydroxycholesterol

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen